AGIO vs BEAM: which is the better buy in 2026?
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
A rare disease franchise turning into a multi-indication PK activator platform, with sickle cell as the swing factor.
Full AGIO analysisBeam Therapeutics
NASDAQ:BEAM
Beam's base editing platform is approaching its first real clinical readouts with enough cash to get there, and the market still prices it like science fiction.
Full BEAM analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is AGIO or BEAM the better buy in 2026?
AGIO and BEAM are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.
How does Alexandria compare AGIO and BEAM?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.